Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
Article
Google Scholar
Park S, Han W, Kim J, Kim MK, Lee E, Yoo T-K, Lee H-B, Kang YJ, Kim Y-G, Moon H-G, et al. Risk factors associated with distant metastasis and survival outcomes in breast Cancer patients with Locoregional recurrence. J Breast Cancer. 2015;18(2):160–6.
Article
Google Scholar
Sirohi B, Leary A, Johnston SRD. Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy? Breast J. 2009;15(3):268–78.
Article
Google Scholar
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
Article
CAS
Google Scholar
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.
Article
Google Scholar
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin Cancer Res. 2010;16(21):5222–32.
Article
Google Scholar
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.
Article
Google Scholar
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genet. 2015;8(1):54.
Google Scholar
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast Cancer treated with Anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.
Article
Google Scholar
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast Cancer. N Engl J Med. 2004;351(27):2817–26.
Article
CAS
Google Scholar
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–14.
Article
CAS
Google Scholar
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012–20.
Article
CAS
Google Scholar
Bertucci F, Finetti P, Viens P, Birnbaum D. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett. 2014;355(1):70–5.
Article
CAS
Google Scholar
Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thürlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, et al. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010;10(1):37.
Article
Google Scholar
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
Article
Google Scholar
Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard P, Parker J. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.
Article
CAS
Google Scholar
Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Ann Oncol. 2012;23(12):2997–3006.
Article
CAS
Google Scholar
Gendoo DMA, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, Haibe-Kains B. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32(7):1097–9.
Article
CAS
Google Scholar
Oberli A, Popovici V, Delorenzi M, Baltzer A, Antonov J, Matthey S, Aebi S, Altermatt H, Jaggi R. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med Genet. 2008;1(1):9.
Google Scholar
Schobesberger M, Baltzer A, Oberli A, Kappeler A, Gugger M, Burger H, Jaggi R. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMC Cancer. 2008;8(1):343.
Article
Google Scholar
Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D, Fell H, Ferree S, George R, Grogan T. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–25.
Article
CAS
Google Scholar
Waggott D, Chu K, Yin S, Wouters BG, Liu F-F, Boutros PC. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012;28(11):1546–8.
Article
CAS
Google Scholar
Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95(25):14863–8.
Article
CAS
Google Scholar
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550–5.
Article
CAS
Google Scholar
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast Cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262–72.
Article
CAS
Google Scholar
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465–72.
Article
CAS
Google Scholar
Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast Cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91.
Article
Google Scholar
Wen G, Zhang J-S, Zhang Y-J, Zhu Y-J, Huang X-B, Guan X-X. Predictive value of molecular subtyping for Locoregional recurrence in early-stage breast Cancer with N1 without Postmastectomy radiotherapy. J Breast Cancer. 2016;19(2):176–84.
Article
Google Scholar
Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic subtype switching and acquired erbb2/her2 amplifications and mutations in breast cancer brain metastases. JAMA Oncology. 2017;3(5):666–71.
Article
Google Scholar
Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015;35:85–95.
Article
CAS
Google Scholar
Oehrlich NE, Spineli LM, Papendorf F, Park-Simon T-W. Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncol Lett. 2017;14(1):194–200.
Article
CAS
Google Scholar
Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong J-H, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, et al. 21-gene recurrence score and Locoregional recurrence in node-positive/ER-positive breast Cancer treated with chemo-endocrine therapy. JNCI. J Natl Cancer Inst. 2017;109(4):1–8.
Article
Google Scholar
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D Jr. CEG, Wickerham DL, Wolmark N: association between the 21-gene recurrence score assay and risk of Locoregional recurrence in node-negative, estrogen receptor–positive breast Cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677–83.
Article
Google Scholar
Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer. 2015;112(8):1405–10.
Article
CAS
Google Scholar
Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, et al. Search for a gene expression signature of breast Cancer local recurrence in young women. Clin Cancer Res. 2012;18(6):1704–15.
Article
CAS
Google Scholar
Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, Tausch C, Trojan A, Moch H. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast Cancer. PLoS One. 2013;8(3):e58483.
Article
CAS
Google Scholar
Alvarado MD, Prasad C, Rothney M, Cherbavaz DB, Sing AP, Baehner FL, Svedman C, Markopoulos CJ. A prospective comparison of the 21-gene recurrence score and the PAM50-based Prosigna in estrogen receptor-positive early-stage breast Cancer. Adv Ther. 2015;32(12):1237–47.
Article
CAS
Google Scholar
Jaggi R, Varga Z, Bigler M, Bize V, Bustamante Eduardo M, Berardi S, Chiesa F, Dedes KJ, Müller A, Tausch C, et al. A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10). Eur J Cancer. 1971;2015(51):S324.
Google Scholar